Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
Université Libre de Bruxelles · Peter MacCallum Cancer Centre · +11 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,264
total citations
- FWCI
- 57.43
- Percentile
- 100%
- References
- 42
Citations per year
Authors
16- SLSherene LoiCorresponding
Université Libre de Bruxelles, Peter MacCallum Cancer Centre, Institut Jules Bordet
- SMStefan Michiels
Université Paris-Sud, Université Libre de Bruxelles, Institut Jules Bordet, Institut Gustave Roussy
- RSRoberto Salgado
Institut Jules Bordet
- NSNicolas Sirtaine
Institut Jules Bordet
- VJVinu José
Université Libre de Bruxelles, Institut Jules Bordet
Topics & keywords
Topics
Keywords
- Medicine
- Trastuzumab
- Oncology
- Breast cancer
- Internal medicine
- Cancer
- Triple-negative breast cancer
- Tumor-infiltrating lymphocytes
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.